BiotechTube

Teniposide administration

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases

Trial Timeline

Feb 7, 2025 → Dec 31, 2026

NCT ID
NCT06758700

About Teniposide administration

Teniposide administration is a phase 2 stage product being developed by China Resources Pharmaceutical Group for Extensive-stage Small Cell Lung Cancer (ES-SCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06758700. Target conditions include Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06758700Phase 2Recruiting

Competing Products

20 competing products in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

See all competitors
ProductCompanyStageHype Score
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3
77
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Atezolizumab 1200 mg in 20 ML Injection + ADC Vaccine + CarboplatinRochePhase 1/2
41
Tarlatamab + DurvalumabAmgenPhase 3
76
Carfilzomib + Carboplatin + EtoposideAmgenPhase 1/2
40
Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / CisplatinInnovent BiologicsPhase 2
51
Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
76
BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
76
BMS-986012 + Carboplatin + Etoposide + NivolumabBristol Myers SquibbPhase 2
51
Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)AkesoPhase 2
51
BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + TopotecanBioNTechPhase 2
49
ZepzelcaJazz PharmaceuticalsPre-clinical
20
Lurbinectedin + DurvalumabJazz PharmaceuticalsPhase 2
49
Surufatinib + Anti-PD-1/L1HUTCHMEDPhase 2
47

Other Products from China Resources Pharmaceutical Group

Shenfu Zhusheye + 5% glucose injectionApproved
82
Jinfukang oral liquid + Platinum-based doublet chemotherapyApproved
82
Yuxuebi tablet + Placebo tabletApproved
82
Mifepristone tabletsApproved
82
Shenfu Injection + 5% Glucose InjectionApproved
82